证券代码：688580 证券简称：伟思医疗 公告编号：2025-045 一、交易概述 南京伟思医疗科技股份有限公司 关于出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 交易简要内容:南京伟思医疗科技股份有限公司（以下简称："公司"或"伟思医疗"）拟以总价人民币 11,900 万元的价格，将其持有的位于南京市雨花台区宁双路19号9幢 的房屋及楼宇部分配套固定资产 （以下简称"标的资产"）转让给江苏云智汇创业投资有限公司（以下简称"本次交易"）。 ● 本次交易不构成关联交易 ● 本次交易不构成重大资产重组 ● 交易实施尚需履行的审批及其他相关程序：本次交易已经公司第四届董事会第八次会议审议通过，根 据《上海证券交易所科创板股票上市规则》的规定，该议案无需提交股东会审议。后续交易双方将按照 签署的《南京市存量房买卖合同》、《固定资产买卖合同》约定办理资产交付等事宜。 ● 风险提示：经公司初步估算，本次交易预计对公司2026年度归属于上市公司股东的净利润影响金额约 为1,000万元（未经审计），对2 ...

Group 1 - The core point of the article is that Weisi Medical plans to transfer its headquarters assets for a total price of 119 million yuan to optimize its asset structure and enhance liquidity [2] - The asset being transferred is located at No. 19, Ning Shuang Road, Yuhuatai District, Nanjing, and has a book net value of 79.9486 million yuan as of September 30, 2025 [3] - The transaction is expected to impact the company's net profit attributable to shareholders by approximately 10 million yuan in 2026, with no effect on the operating revenue and net profit for 2025 [3] Group 2 - Weisi Medical's new headquarters, "Weisi Medical Headquarters R&D Economic Park," has successfully passed construction acceptance and is ready for efficient operation [3] - The company specializes in rehabilitation medical equipment, reporting operating revenue of 326 million yuan for the first three quarters of 2025, a year-on-year increase of 11.58% [3] - The net profit attributable to shareholders for the same period was 102 million yuan, reflecting a year-on-year growth of 30.68% [3]

（记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 截至发稿，伟思医疗市值为45亿元。 每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 每经AI快讯，伟思医疗（SH 688580，收盘价：47.06元）12月22日晚间发布公告称，南京伟思医疗科技 股份有限公司拟以总价人民币1.19亿元的价格，将其持有的位于南京市雨花台区宁双路19号9幢的房屋 及楼宇部分配套固定资产转让给江苏云智汇创业投资有限公司。 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 每日经济新闻 ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 伟思医疗(688580.SH)公告称，公司拟以总价1.19亿元的价格，将持有的位于南京市雨花台区宁双路19号 9幢的房屋及楼宇部分配套固定资产，转让给江苏云智汇创业投资有限公司。此次交易预计对公司2026 年度归属于上市公司股东的净利润的影响金额约为1000万元。 ...

Core Viewpoint - Weisi Medical (688580) announced the transfer of its property and associated fixed assets in Nanjing for a total price of 119 million yuan, aiming to optimize asset utilization and support its strategic goals [1] Group 1: Transaction Details - The company plans to sell its property located at No. 19, Ning Shuang Road, Yuhua District, Nanjing to Jiangsu Yunzhi Hui Venture Capital Co., Ltd. for 119 million yuan [1] - This transaction is intended to address the issue of idle assets following relocation and to reduce operational costs [1] Group 2: Strategic Implications - The proceeds from the sale will be used to fund the operation of the new headquarters and the development of core business activities [1] - The decision aligns with the company's long-term strategy and benefits all shareholders [1]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-045 南京伟思医疗科技股份有限公司 关于出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容:南京伟思医疗科技股份有限公司（以下简称："公司" 或"伟思医疗"）拟以总价人民币 11,900 万元的价格，将其持有的位于南京 市雨花台区宁双路 19 号 9 幢 的房屋及楼宇部分配套固定资产（以下简称"标 的资产"）转让给江苏云智汇创业投资有限公司（以下简称"本次交易"）。 交易实施尚需履行的审批及其他相关程序：本次交易已经公司第四届 董事会第八次会议审议通过，根据《上海证券交易所科创板股票上市规则》 的规定，该议案无需提交股东会审议。后续交易双方将按照签署的《南京市 存量房买卖合同》、《固定资产买卖合同》约定办理资产交付等事宜。 风险提示：经公司初步估算，本次交易预计对公司 2026 年度归属于 上市公司股东的净利润影响金额约为 1,000 万元（未经审计），对 2025 年当 期营业收入及净利润无任何影响，最终财务数据以公司 ...

每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，伟思医疗（SH 688580，收盘价：47.06元）12月22日晚间发布公告称，公司第四届第八次 董事会会议于2025年12月19日在公司会议室召开。会议审议了《关于出售资产的议案》等文件。 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 截至发稿，伟思医疗市值为45亿元。 ...

Core Viewpoint - Weisi Medical (688580.SH) has successfully completed the construction acceptance of its new headquarters, the "Weisi Medical Headquarters R&D Economic Park," which is expected to enhance operational efficiency and support the company's high-quality development [1] Group 1: New Headquarters Development - The new headquarters is located at No. 1 Shuo Guo Road, Yuhua District, Nanjing, covering an area of approximately 24,000 square meters with a total construction area of nearly 70,000 square meters [1] - The facility integrates high-end research and development, intelligent manufacturing, and modern office functions, significantly improving the office environment, production capacity, research infrastructure, and intelligence level compared to the current location [1] - The company plans to complete the overall relocation by the first half of 2026, which will provide a solid foundation for its high-quality development [1] Group 2: Asset Optimization and Financial Strategy - To optimize its asset structure and enhance resource allocation efficiency, the company plans to dispose of its current headquarters located at No. 19 Ning Shuang Road, Yuhua District, Nanjing [1] - The agreed total transfer price for the disposal of the property and associated facilities is RMB 119 million (equivalent to 11,900 million yuan) [1] - This disposal will help activate existing assets, address potential idle issues post-relocation, reduce operational costs, and recover funds for the new headquarters operations and core business development, aligning with the company's long-term strategy and benefiting all shareholders [1]

伟思医疗12月22日公告，为优化资产结构、提升资源配置效率并增强资金流动性，公司拟以总价1.19亿 元出售位于南京市雨花台区宁双路19号9幢的房屋及楼宇部分配套固定资产。本次交易预计对公司2026 年度归属于上市公司股东的净利润影响金额约为1000万元，对2025年当期营业收入及净利润无任何影 响。 ...